Nicholas Choong

Nicholas Choong

Company: Seagen

Job title: Vice President of Clinical Development


Disitamab Vedotin: A Novel HER2 ADC 9:30 am

– Disitamab vedotin is a HER2 ADC with an antibody designed to maximize drug delivery with higher affinity and internalization rate as compared to trastuzumab in preclinical models – Exploring DV’s encouraging monotherapy clinical data across a range of HER2 expressing solid tumors – Understanding how DV has demonstrated combination activity preclinically and clinically with…Read more

day: Day One

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.